When was Poseida Therapeutics founded?

Poseida Therapeutics was founded in 2015 and raised its 1st funding round within a year of its incorporation.

Where is Poseida Therapeutics located?

Poseida Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California.

How many employees does Poseida Therapeutics have?

As of May 31, 2026, the latest employee count at Poseida Therapeutics is 85.

Is Poseida Therapeutics a funded company?

Poseida Therapeutics is a funded company, having raised a total of $324M across 6 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Dec 23, 2015.

How much is Poseida Therapeutics worth?

The last known valuation of Poseida Therapeutics was $***** as of Nov 26, 2024.

When was the latest funding round of Poseida Therapeutics?

Poseida Therapeutics' latest funding was a $***** Post IPO round on Aug 07, 2023, with participation from 1 investor.

What is the annual revenue of Poseida Therapeutics?

Annual revenue of Poseida Therapeutics is $64.7M as on Dec 31, 2023.

Where does Poseida Therapeutics rank among its competitors?

Poseida Therapeutics ranks 50th amongst 679 active competitors, of which 257 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Caris Life Sciences, which secured $168M in Apr, 2025.

Who are the top competitors of Poseida Therapeutics?

Poseida Therapeutics' top competitors include Senti Biosciences, Denali Therapeutics and Caris Life Sciences. Among them, Caris Life Sciences secured the most recent funding round in April, 2025.

Poseida Therapeutics - 2026 Company Profile, Funding, Competitors & Financials

Q: Is Poseida Therapeutics an acquired company?

Poseida Therapeutics got acquired by Roche on Nov 26, 2024.

Poseida Therapeutics is an acquired company based in San Diego (United States), founded in 2015. It operates as a Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies. Poseida Therapeutics has raised $324M in funding from investors like Fidelity Investments, Novartis and Longitude Capital, with last known valuation of $*****. The company has 679 active competitors, including 257 funded and 162 that have exited. Its top competitors include companies like Senti Biosciences, Denali Therapeutics and Caris Life Sciences.

Company Details

Developer of gene therapies for treating cancer and liver orphan disease by using gene-editing technologies. It is developing CAR-T and gene therapy products for cancer and orphan diseases. Poseida uses its genome engineering capabilities for effectively silencing target genes or inserting therapeutic genes. Proprietary tools include piggyBac DNA Modification System, CRISPR, TALEN, and Footprint-Free Gene Editing System, which are clean (synthetic and virus-free) and can be surgically precise.

Website: poseida.com
Social
Registered Address: San Diego, California

Key Metrics

Founded Year

2015

Location

San Diego, United States

Stage

Acquired

Total Funding

$324M in 6 rounds

Latest Funding Round

Post IPO, Aug 07, 2023, $*****

Last Known Valuation

$***** as on Nov 26, 2024

Investors

Fidelity Investments & 13 more

Ranked

50^th among 679 active competitors

Annual Revenue

$64.7M as on Dec 31, 2023

Employee Count

85 as on May 31, 2026

Similar Companies

Senti Biosciences & 877 more

Exit Details

Acquired by Roche (Nov 26, 2024)

View Poseida Therapeutics' full profile

Poseida Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Poseida Therapeutics, Inc. CIN: 472846548 , United States, Active	Dec 31, 2014	$64.7M (As on Dec 31, 2023)	348 (As on Dec 31, 2024)	-

Poseida Therapeutics got acquired by Roche on Nov 26, 2024 at an acquisition amount of $*****.

Click here to take a look at Poseida Therapeutics's acquisition in detail

Poseida Therapeutics has raised a total funding of $324M over 6 rounds. Its first funding round was on Dec 23, 2015. Its latest funding round was a Post IPO round on Aug 07, 2023 for $*****. 1 investor participated in its latest round. Poseida Therapeutics has 14 institutional investors.

Here is the list of recent funding rounds of Poseida Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 07, 2023	6634857	Post IPO	2733708	9593732	8665288	8566420
Jun 25, 2020	9278284	Series D	9987814	7131359	3169653	Rapha Capital Management & 2 more
Apr 22, 2019	8725648	Series C	6389397	8641892	Novartis	Aisling Capital & 6 more

Access funding benchmarks and valuations. Sign up today!

View details of Poseida Therapeutics's funding rounds and investors

Poseida Therapeutics' employee count trend

Poseida Therapeutics has 85 employees as of May 26. Here is Poseida Therapeutics's employee count trend over the years:

Employee count trend for Poseida Therapeutics

Uncover Poseida Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Poseida Therapeutics include Senti Biosciences, Denali Therapeutics and Caris Life Sciences. Here is the list of Top 10 competitors of Poseida Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Senti Biosciences 2016, San Francisco (United States), Public	Developer of cell-based therapies for cancer treatment	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
2nd	Denali Therapeutics 2015, San Francisco (United States), Public	Developer of therapies to treat neurodegenerative diseases	$347M	Baillie Gifford, Bezos Expeditions & 10 others	72/100
3rd	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Coatue & 19 others	71/100
4th	TScan Therapeutics 1995, Boston (United States), Public	Developer of T cell therapies to harness the immune system against cancer	$180M	RA Capital Management, BlackRock & 9 others	70/100
5th	Immuneel 2018, Bengaluru (India), Series A	Developer of T-cell therapies for the treatment of cancer	$39.3M	Khosla Ventures, True North & 20 others	70/100
6th	ImmunoACT 2018, Mumbai (India), Series B	Developer of cell and gene therapies for cancer treatment	$15.9M	SINE, Laurus Labs & 4 others	69/100
7th	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, BB Biotech & 10 others	68/100
8th	Geneoscopy 2015, St. Louis (United States), Series C	Developer of non-invasive biomarker tests for colorectal cancer	$219M	LightChain Capital, Cultivation Capital & 18 others	67/100
9th	Immatics 2000, Tubingen (Germany), Public	Developer of T -cell-based immunotherapies for the treatment of cancer	$236M	Wellington Partners Venture Capital, Dievini ... & 18 others	67/100
10th	Intellia Therapeutics 2014, Cambridge (United States), Public	Developer of therapeutics based on CRISPR/Cas9 technology for multiple diseases	$85M	Orbimed, Novartis & 10 others	66/100
50th	Poseida Therapeutics 2015, San Diego (United States), Acquired	Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies	$324M	Boxer Capital, Fidelity Investments & 12 others	60/100